GB1377308A - Pyrimidones - Google Patents
PyrimidonesInfo
- Publication number
- GB1377308A GB1377308A GB774872A GB774872A GB1377308A GB 1377308 A GB1377308 A GB 1377308A GB 774872 A GB774872 A GB 774872A GB 774872 A GB774872 A GB 774872A GB 1377308 A GB1377308 A GB 1377308A
- Authority
- GB
- United Kingdom
- Prior art keywords
- methyl
- prepared
- hydrogen
- reacting
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000008318 pyrimidones Chemical class 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N 1,1-Diethoxyethane Chemical compound CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 abstract 1
- QNIXWENUBKZJKM-UHFFFAOYSA-N 2-(4-chlorophenoxy)-3-(dimethylamino)prop-2-enal Chemical compound CN(C)C=C(C=O)OC1=CC=C(Cl)C=C1 QNIXWENUBKZJKM-UHFFFAOYSA-N 0.000 abstract 1
- OVXJWSYBABKZMD-UHFFFAOYSA-N 2-chloro-1,1-diethoxyethane Chemical compound CCOC(CCl)OCC OVXJWSYBABKZMD-UHFFFAOYSA-N 0.000 abstract 1
- LRJBWZLCGVAROW-UHFFFAOYSA-N 5-phenylsulfanyl-1h-pyrimidin-2-one Chemical class C1=NC(O)=NC=C1SC1=CC=CC=C1 LRJBWZLCGVAROW-UHFFFAOYSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000005864 Sulphur Substances 0.000 abstract 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 1
- 229910052783 alkali metal Inorganic materials 0.000 abstract 1
- 150000001340 alkali metals Chemical class 0.000 abstract 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 abstract 1
- -1 alkaline earth metal salt Chemical class 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 230000003182 bronchodilatating effect Effects 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 230000027119 gastric acid secretion Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- HMSLXWQWEJXFFR-UHFFFAOYSA-M potassium;4-chlorophenolate Chemical compound [K+].[O-]C1=CC=C(Cl)C=C1 HMSLXWQWEJXFFR-UHFFFAOYSA-M 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19400671A | 1971-10-29 | 1971-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1377308A true GB1377308A (en) | 1974-12-11 |
Family
ID=22715935
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB774872A Expired GB1377308A (en) | 1971-10-29 | 1972-02-18 | Pyrimidones |
| GB5005373A Expired GB1377720A (en) | 1971-10-29 | 1972-02-18 | Hydroxy pyrimidines |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB5005373A Expired GB1377720A (en) | 1971-10-29 | 1972-02-18 | Hydroxy pyrimidines |
Country Status (25)
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776870B2 (en) | 2005-08-22 | 2010-08-17 | Melior Pharmaceuticals I, Inc. | Methods for modulating Lyn kinase activity and treating related disorders |
| US8552184B2 (en) | 2008-07-03 | 2013-10-08 | Melior Pharmaceuticals I, Inc. | Compounds and methods for treating disorders related to glucose metabolism |
| US10786503B2 (en) | 2017-04-10 | 2020-09-29 | Melior Pharmaceuticals I, Inc. | Treatment of adipocytes |
| US12011445B2 (en) | 2010-05-28 | 2024-06-18 | Melior Pharmaceuticals I, Inc. | Prevention of pancreatic cell degeneration |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55151912U (enrdf_load_stackoverflow) * | 1979-04-17 | 1980-11-01 | ||
| DE3222914A1 (de) * | 1982-06-18 | 1983-12-22 | Beiersdorf Ag, 2000 Hamburg | Substituierte 5-phenylthio-6-amino-pyrimidinone, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen |
| JPH0655686B2 (ja) * | 1988-08-30 | 1994-07-27 | 宇部興産株式会社 | ｐ−ブロモフェノキシアセトアルデヒドジアルキルアセタール類の製造方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2913462A (en) * | 1959-11-17 | Eahl h | ||
| GB951431A (en) * | 1959-03-17 | 1964-03-04 | Wellcome Found | Pyrimidine derivatives and the manufacture thereof |
-
0
- BE BE790125D patent/BE790125A/xx not_active IP Right Cessation
-
1972
- 1972-02-18 GB GB774872A patent/GB1377308A/en not_active Expired
- 1972-02-18 GB GB5005373A patent/GB1377720A/en not_active Expired
- 1972-09-25 SE SE7212358A patent/SE393376B/xx unknown
- 1972-09-28 AU AU47228/72A patent/AU467600B2/en not_active Expired
- 1972-09-28 IL IL40458A patent/IL40458A/en unknown
- 1972-10-02 PH PH13959A patent/PH10129A/en unknown
- 1972-10-05 DE DE2264657A patent/DE2264657C2/de not_active Expired
- 1972-10-05 DE DE2264374A patent/DE2264374C3/de not_active Expired
- 1972-10-05 DE DE2248741A patent/DE2248741C3/de not_active Expired
- 1972-10-06 AT AT858972A patent/AT321308B/de not_active IP Right Cessation
- 1972-10-06 AT AT00933/74A patent/AT320656B/de not_active IP Right Cessation
- 1972-10-12 YU YU2551/72A patent/YU35125B/xx unknown
- 1972-10-12 FI FI2825/72A patent/FI55503C/fi active
- 1972-10-13 NO NO3686/72A patent/NO136574C/no unknown
- 1972-10-13 SU SU1839308A patent/SU498908A3/ru active
- 1972-10-16 PL PL1972158297A patent/PL84634B1/pl unknown
- 1972-10-16 IE IE1398/72A patent/IE37043B1/xx unknown
- 1972-10-16 CH CH165674A patent/CH549579A/fr not_active IP Right Cessation
- 1972-10-16 LU LU66304A patent/LU66304A1/xx unknown
- 1972-10-16 CH CH1507872A patent/CH555832A/fr not_active IP Right Cessation
- 1972-10-16 ZA ZA727362A patent/ZA727362B/xx unknown
- 1972-10-16 FR FR7236560A patent/FR2157865B1/fr not_active Expired
- 1972-10-16 DK DK510072AA patent/DK131465B/da not_active IP Right Cessation
- 1972-10-16 CA CA153,956A patent/CA980778A/en not_active Expired
- 1972-10-16 PL PL1972174103A patent/PL89852B1/pl unknown
- 1972-10-16 JP JP10279972A patent/JPS5337870B2/ja not_active Expired
- 1972-10-16 NL NL7213959.A patent/NL166470C/xx not_active IP Right Cessation
- 1972-10-18 ES ES407730A patent/ES407730A1/es not_active Expired
- 1972-10-19 EG EG431/72A patent/EG11013A/xx active
- 1972-10-23 AR AR244763A patent/AR198798A1/es active
-
1973
- 1973-07-12 AR AR249053A patent/AR196263A1/es active
-
1974
- 1974-03-26 SU SU2008490A patent/SU505362A3/ru active
-
1975
- 1975-04-15 ES ES436624A patent/ES436624A1/es not_active Expired
- 1975-05-06 SE SE7505279A patent/SE397090B/xx unknown
- 1975-11-21 PH PH17784A patent/PH11594A/en unknown
-
1976
- 1976-01-05 IL IL48790A patent/IL48790A/en unknown
-
1978
- 1978-02-08 JP JP1336078A patent/JPS53116386A/ja active Granted
-
1979
- 1979-04-25 YU YU991/79A patent/YU36295B/xx unknown
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10251883B2 (en) | 2005-08-22 | 2019-04-09 | Melior Pharmaceuticals I, Inc. | Methods and formulations for modulating Lyn kinase activity and treating related disorders |
| US8343985B2 (en) | 2005-08-22 | 2013-01-01 | Melior Pharmaceuticals I, Inc. | Methods for modulating Lyn kinase activity and treating related disorders |
| US8835448B2 (en) | 2005-08-22 | 2014-09-16 | Melior Pharmaceuticals I, Inc. | Methods and formulations for modulating lyn kinase activity and treating related disorders |
| US9216959B2 (en) | 2005-08-22 | 2015-12-22 | Melior Pharmaceuticals I, Inc. | Methods and formulations for treating cardiovascular disease |
| US9763945B2 (en) | 2005-08-22 | 2017-09-19 | Melior Pharmaceuticals I, Inc. | Methods and formulations for modulating Lyn kinase activity and treating related disorders |
| US7776870B2 (en) | 2005-08-22 | 2010-08-17 | Melior Pharmaceuticals I, Inc. | Methods for modulating Lyn kinase activity and treating related disorders |
| US11033548B2 (en) | 2005-08-22 | 2021-06-15 | Melior Pharmaceuticals I, Inc. | Methods and formulations for modulating Lyn kinase activity and treating related disorders |
| US12070461B2 (en) | 2005-08-22 | 2024-08-27 | Melior Pharmaceuticals I, Inc. | Methods and formulations for modulating Lyn kinase activity and treating related disorders |
| US8552184B2 (en) | 2008-07-03 | 2013-10-08 | Melior Pharmaceuticals I, Inc. | Compounds and methods for treating disorders related to glucose metabolism |
| US12011445B2 (en) | 2010-05-28 | 2024-06-18 | Melior Pharmaceuticals I, Inc. | Prevention of pancreatic cell degeneration |
| US10786503B2 (en) | 2017-04-10 | 2020-09-29 | Melior Pharmaceuticals I, Inc. | Treatment of adipocytes |
| US11534442B2 (en) | 2017-04-10 | 2022-12-27 | Melior Pharmaceuticals I, Inc. | Treatment of adipocytes |
| US12064432B2 (en) | 2017-04-10 | 2024-08-20 | Melior Pharmaceuticals I, Inc. | Treatment of adipocytes |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES480542A1 (es) | Metodo para producir derivados de imidazol. | |
| GB1359563A (en) | Pyrazolo-pyrimidines useful as xanthine oxidase inhibitors | |
| GB1506914A (en) | 2-dihalophenylamino-2-imidazoline derivatives | |
| GB1377308A (en) | Pyrimidones | |
| GB1411583A (en) | Aminophenyl-substituted alkyl-heterocyclic derivatives and processes for producing them | |
| GB1429141A (en) | 1-substituted pyrazol-5-ones their production and their medicinal use | |
| GB1456627A (en) | Pyridobenzodiazepinones | |
| GB1495665A (en) | Pyrimidines | |
| GB1168391A (en) | Substituted Uracils | |
| IL40329A (en) | History of pyridine, their production and use as antimicrobial agents | |
| GB1328935A (en) | Substituted cycloalkyl lactamimides | |
| GB1316894A (en) | Benzimidazole derivatives | |
| SE7415015L (sv) | Sett att framstella nya 2-fenylhydrazino-tiazoliner eller -tiaziner | |
| GB1445765A (en) | Phenoxy-substituted malonic acid derivatives their prepration and pharmaceutical compositions containing them | |
| GB1164555A (en) | New Tropine Derivatives | |
| GB1131164A (en) | Novel halogen-substituted tetrahydroquinazoline derivatives, their preparation and compositions containing them | |
| GB1500962A (en) | Furo(2,3-d)pyrimidine derivatives | |
| GB1353545A (en) | S-triazine derivatives and their salts and process for producing them | |
| GB1254270A (en) | Benzoxazepine derivatives | |
| GB1373276A (en) | 2-aryl-amino-imidazoline-2 compounds | |
| GB1203430A (en) | Heterocyclic spiro compounds | |
| GB1227967A (enrdf_load_stackoverflow) | ||
| GB1242096A (en) | Benzobenzofuranooxepine compounds and process for preparing the same | |
| GB1409828A (en) | Pharmaceuticals and process for their preparation | |
| GB1504683A (en) | Pharmaceutical compositions containing substituted pyrimido-quinoline derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| PCNP | Patent ceased through non-payment of renewal fee |